CellPhire

About:

Cellphire has developed a proprietary method for the stabilization of blood in the dry state

Website: http://www.cellphire.com/

Top Investors: Maryland Venture Fund, Simcah Management

Description:

Cellphire has developed a proprietary method for the stabilization of blood in the dry state Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. We have been able to stabilize and modify platelets into a hemostatic agent that can be stored well beyond the current limit of 5 days. Platelets cannot be stockpiled and shortages occur because of this extremely short shelf life. These shortages can interrupt the treatment of cancer patients and actively bleeding surgical or trauma patients. The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt or exceed the available supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.

Total Funding Amount:

$18M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rockville, Maryland, United States

Founded Date:

2005-01-01

Contact Email:

support(AT)cellphire.com

Founders:

Richard Cliff

Number of Employees:

11-50

Last Funding Date:

2023-10-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai